Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
526 hedge funds and large institutions have $18.8B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 217 increasing their positions, 163 reducing their positions, and 55 closing their positions.
125% more call options, than puts
Call options by funds: $164M | Put options by funds: $72.8M
33% more repeat investments, than reductions
Existing positions increased: 217 | Existing positions reduced: 163
25% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 55
2% more funds holding
Funds holding: 516 → 526 (+10)
2% more capital invested
Capital invested by funds: $18.4B → $18.8B (+$350M)
19% less funds holding in top 10
Funds holding in top 10: 31 → 25 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$144M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$101M |
| 3 |
State Street
Boston,
Massachusetts
|
+$99.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$97.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$80.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$163M |
| 2 |
BlackRock
New York
|
-$128M |
| 3 |
D.E. Shaw & Co
New York
|
-$110M |
| 4 |
Renaissance Technologies
New York
|
-$89.5M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$87M |
HZNP Hedge Fund Activity: Q2 2021 in Review
526 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2021, worth a combined $18.8B — up 1.9% from $18.4B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new HZNP positions and 55 closed out — a net gain of 14 holders — while 217 added to existing stakes and 163 trimmed.
The largest buyer was Macquarie Group, adding an estimated $144M. The largest seller was Janus Henderson Group, cutting an estimated $163M.
- 526 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2021, up from 516 in Q1 2021.
- Funds reported $18.8B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2021, up 1.9% quarter-over-quarter.
- 69 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2021 and 55 closed out, a net change of +14 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2021 was Macquarie Group, an estimated $144M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2021 was Janus Henderson Group, an estimated $163M sold.
Based on aggregated 13F filings for Q2 2021.